Adherex Technologies Inc. has activated a phase III trial of sodium thiosulfate (STS) vs placebo to prevent hearing loss in children scheduled to receive cisplatin-based chemotherapy for newly diagnosed germ cell, liver, brain, nerve tissue, or bone cancers.
RESERACH TRIANGLE PARK, North Carolina-Adherex Technologies Inc. has activated a phase III trial of sodium thiosulfate (STS) vs placebo to prevent hearing loss in children scheduled to receive cisplatin-based chemotherapy for newly diagnosed germ cell, liver, brain, nerve tissue, or bone cancers. The trial, being conducted in collaboration with the Children’s Oncology Group, is expected to enroll up to 120 patients.
Elevating the Quality of Cancer Care via Cross-Department Collaboration
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
Elevating the Quality of Cancer Care via Cross-Department Collaboration
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
2 Commerce Drive
Cranbury, NJ 08512